Therapeutic antibodies are increasingly used to treat various diseases, including neoplasms
and chronic inflammatory diseases. Antibodies exhibit complex pharmacokinetic properties …

Purpose: An ancillary phase II study was conducted to study interindividual variability in
cetuximab pharmacokinetics and its influence on progression-free survival (PFS) in …

Monoclonal antibodies (mAbs) are usually delivered systemically, but only a small
proportion of the drug reaches the lung after intravenous injection. The inhalation route is an …

Purpose Lung cancer is the leading cause of cancer-related death worldwide. The efficacy
of current systemic treatments is limited, with major side effects and only modest survival …

Objective Clinical response to bevacizumab varies between patients treated for metastatic
colorectal cancer (mCRC). The aim of this study was to quantify individual factors affecting …

Background Bevacizumab—a humanized monoclonal antibody—has been widely used to
treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has …

The neonatal Fc receptor (FcRn) encoded by FCGRT is known to be involved in the
pharmacokinetics (PK) of therapeutic monoclonal antibodies (mAbs). Variability in the …

Objective To identify patient characteristics associated with responsiveness to tumour
necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). Materials and methods …

Adalimumab, an anti-TNF-α monoclonal antibody, is approved for the treatment of
rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, Crohn's disease (CD) …

Cetuximab is an anti-epidermal growth factor receptor monoclonal antibody used in the
treatment of colorectal and head and neck cancers. Part of the interindividual differences in …